AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.
Acoramidis reduces all-cause mortality in ATTR-CM
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Daniel Judge, MD is a professor of medicine in cardiology at Medical University of South Carolina (MUSC) in Charleston, SC, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of ATTRibute-CM-OLE have been published in Circulation
Release date: 18 November 2024
Recommended
Details
Presenters
Overview
AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Daniel Judge, MD is a professor of medicine in cardiology at Medical University of South Carolina (MUSC) in Charleston, SC, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of ATTRibute-CM-OLE have been published in Circulation
Release date: 18 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?